Keith Pfeil is recorded as COO at Globus Medical Inc (GMED) since February 1, 2024 and CEO and Board Member at Globus Medical Inc (GMED). Globus Medical Inc reported in an 8-K filed February 5, 2024 that Keith Pfeil was appointed Chief Operating Officer and Chief Financial Officer, effective February 1, 2024. The proxy statement of Globus Medical Inc reports total compensation of $2,063,448 for Keith Pfeil in fiscal 2023, including a base salary of $414,690. Disclosed compensation is on record for 5 fiscal years. Keith Pfeil has spoken on 23 earnings calls across 1 company, most recently for Globus Medical Inc on November 6, 2025. Globus Medical Inc is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Globus Medical Inc includes Keith W. Pfeil (CEO and Board Member), David C. Paul (Chairman and Board Member), Kyle R. Kline (CFO) and 7 others.
“On February 5, 2024, Globus Medical, Inc. (the “Company”) issued a news release announcing the promotion of Keith Pfeil to Chief Operating Officer and Chief Financial Officer, effective as of February 1, 2024.”
Globus Medical Inc Form 8-K, filed February 5, 2024
· Read the filing
Keith Pfeil on recent calls
“We are extremely pleased with our overall Q3 performance, delivering sales of $769 million and non-GAAP diluted earnings per share of $1.18, growing 22.9% and 42.6%, respectively, over the prior year quarter.”
“This is my first earnings call as CEO following our July 21 announcement regarding the leadership transition. I'd like to take a moment to thank David Paul and the Board for their confidence in me.”
“Reflecting on Q1, our quarter delivered a mixed set of results. While revenue was down slightly compared to the prior year quarter, we saw a meaningful expansion in profitability and cash flow.”
“We capped off 2024 with a strong fourth quarter, helping us successfully complete our first combined fiscal year following the September 2023 merger with NuVasive.”
“During our third quarter, we passed the one-year mark since the closing of the NuVasive merger. Much work has been done thus far in becoming the most successful spine integration at the one-year mark, but much work remains.”
